证券代码：300314 证券简称：戴维医疗 公告编号：2025-031 本次延续注册的完成，使得公司可以继续生产和销售经皮黄疸仪，对 公司未来经营将产生积极影响。上述产品的实际销售情况取决于未来市场 推广效果，公司目前尚无法预测其对公司未来业绩的影响，敬请投资者注 意投资风险。 特此公告。 宁波戴维医疗器械股份有限公司 董事会 2025年5月30日 宁波戴维医疗器械股份有限公司 关于公司部分医疗器械产品完成延续注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日取得由 浙江省药品监督管理局颁发的1项《医疗器械注册证》，公司产品经皮黄 疸仪完成了延续注册，具体如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期至 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 1 | 经皮黄疸仪 | 浙械注准 | 2030.11.22 | Ⅱ类 | 用于测量新生儿 | | | | 20202070849 | | | 在光疗前、光疗期 | | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：300314 证券简称：戴维医疗 公告编号：2025-030 宁波戴维医疗器械股份有限公司 关于第一类医疗器械备案信息变更的公告 宁波戴维医疗器械股份有限公司（以下简称"公司"）因生产经 营需要，公司产品医用婴儿床新增了相关型号规格，并于近日取得了 由宁波市市场监督管理局核发的1项《第一类医疗器械备案信息表》， 具体情况如下： 产品名称：医用婴儿床 备案编号：浙甬械备20220083 备案人名称：宁波戴维医疗器械股份有限公司 备案人统一社会信用代码：91330200610257495J 备案人住所：浙江省宁波市象山县石浦科技园区科苑路2号 生产地址：浙江省宁波市象山县石浦科技园区科苑路2号 产品描述：YC-100系列医用婴儿床（以下简称婴儿床）由婴儿盆、 床垫、立柱、储物兜（选配）、储物盆、输液架（选配）和脚轮组成。 产品为无源产品。YC-200系列婴儿床由婴儿盆、支架、床垫、储物筐、 储物兜、储物盆（选配）和脚轮组成。产品为无源产品。 预期用途：用于医疗机构护理、诊疗或转运新生儿、婴儿时使用。 备案日 ...

Core Viewpoint - David Medical's stock closed at 12.4 yuan, down 2.52%, with a rolling PE ratio of 85.59 times, and a total market value of 3.571 billion yuan [1] Company Summary - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with key products including incubators, radiant warmers, jaundice treatment devices, EEG monitors, and more [1] - As of Q1 2025, two institutions held shares in David Medical, with a total of 1.2529 million shares valued at 0.015 billion yuan [1] - The company has received multiple honors, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" and "AAA Credit Rating Enterprise" [1] Industry Summary - The average PE ratio for the medical device industry is 49.46 times, with a median of 36.16 times, placing David Medical at 102nd in the industry ranking [2] - The company's Q1 2025 performance showed a revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.5677 million yuan, down 40.78%, with a gross margin of 57.13% [2]

5月14日，戴维医疗今日收盘12.72元，上涨2.33%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到87.80倍，创26天以来新低，总市值36.63亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.21亿元，同比-22.00%；净利润2256.77万元， 同比-40.78%，销售毛利率57.13%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)102戴维医疗87.8063.973.0736.63亿行业平均 49.8447.964.65106.43亿行业中值36.6538.442.4547.58亿1天益医疗-1720.32-2946.711.8421.92亿2澳华内 镜-589.71295.774.7262.15亿3诺唯赞-415.01-490.852.2888.81亿4爱朋医疗-368.22279.744.4430.21亿5博晖 创新-326.27517.743.4847.87亿6硕世生物-135.93-1986.301.2239.76亿7奥精医疗-120.78-177.021.5922.41亿 8睿昂基因-97.79-80.291.3912.66亿9康泰医学-85. ...

Group 1: Company Performance - Wens Foodstuff's April chicken sales revenue was 2.543 billion yuan, a year-on-year decrease of 5.01% [1] - Wens Foodstuff sold 10.381 million chickens in April, a year-on-year increase of 10.87% [1] - Wens Foodstuff's average chicken selling price was 11.24 yuan/kg, a year-on-year decrease of 14.91% [1] - Zhongtong Bus's April vehicle sales volume was 1,046 units, a year-on-year decrease of 4.04% [1][2] - Kemin Food's April pig sales revenue reached 70.9048 million yuan, a year-on-year increase of 16.04% [3] - Muyuan Foods sold 6.573 million pigs in April, a year-on-year increase of 51.80% [5] - Muyuan Foods' pig sales revenue was 12.595 billion yuan in April, a year-on-year increase of 53.42% [5] - Xiamen Airport's April passenger throughput was 2.3881 million, a year-on-year increase of 7.73% [24] - Daqin Railway's April cargo transport volume was 30.62 million tons, a year-on-year increase of 0.99% [26] - Shaanxi Coal's April coal production was 14.24 million tons, a year-on-year decrease of 1.78% [28] Group 2: Industry Overview - Wens Foodstuff operates in the agriculture, forestry, animal husbandry, and fishery industry, specifically in pig farming [1] - Zhongtong Bus operates in the automotive industry, focusing on commercial vehicles [2] - Kemin Food operates in the food and beverage industry, specifically in food processing [3] - Muyuan Foods is also in the agriculture, forestry, animal husbandry, and fishery industry, focusing on pig farming [5] - Xiamen Airport is part of the transportation industry, specifically in airport operations [24] - Daqin Railway operates in the coal industry, focusing on coal mining and transportation [26] - Shaanxi Coal is also in the coal industry, focusing on coal mining and related services [28]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a decline in revenue and profit while maintaining a high PE ratio compared to industry averages [1][2] - As of May 7, David Medical's stock closed at 12.16 yuan, with a PE ratio of 83.93, which is significantly higher than the industry average of 49.02 and the median of 36.25 [1][2] - The company has a total market capitalization of 3.502 billion yuan, ranking 101st in the medical device industry based on PE ratio [1][2] Group 2 - In the first quarter of 2025, David Medical reported a revenue of 121 million yuan, representing a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% from the previous year [2] - The company's gross profit margin stands at 57.13%, indicating a relatively strong profitability despite the decline in revenue and net profit [2] - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with a range of key products including incubators and neonatal monitoring devices [1]

Core Viewpoint - David Medical (300314) announced that its wholly-owned subsidiary, Ningbo Weier Kaidi Medical Devices Co., Ltd., has received a medical device registration acceptance notice from the Zhejiang Provincial Drug Administration for a disposable cannula puncture device, indicating a positive development for the company's product portfolio [1] Company Summary - The product is classified as a Class II medical device and is primarily used to establish working channels during laparoscopic examinations and surgeries, suggesting a broad application potential across various surgical fields [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-029 宁波戴维医疗器械股份有限公司 关于全资子公司申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子 公司宁波维尔凯迪医疗器械有限公司于近日取得由浙江省药品监督 管理局颁发的1项《受理通知书》，受理号为：械受20254012924。 具体情况如下： | 序号 | 产品名称 | 注册分类 | 临床用途 | | --- | --- | --- | --- | | 1 | 一次性使用套管穿刺器 | II 类 | 供腹腔镜检查和手术过 | | | | | 程中，对人体腹壁组织穿 | | | | | 刺，建立腹腔手术的工作 | | | | | 通道用。 | 上述医疗器械产品目前所处的审批阶段为注册申请受理，后续 所需的审批流程为技术审评、行政审批、制证。上述品种注册申请 受理对公司近期业绩不会产生影响，后续各阶段所需的时间和结果 均具有一定的不确定性，公司将对上述品种的后续进展情况及时履 行信息披露义务。敬请广大投资者予以 ...

北京市金杜（济南）律师事务所（以下简称本所）接受宁波戴维医疗器械股 份有限公司（以下简称公司）的委托，根据本法律意见书出具日前已经发生或存 在的事实和《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）、《上市公司股东会规则》（以下简称 《股东会规则》）等中华人民共和国境内（以下简称中国境内，为本法律意见书 之目的，不包括中国香港特别行政区、中国澳门特别行政区和中国台湾地区）现 行有效的法律、法规和规范性文件以及现行有效的《宁波戴维医疗器械股份有限 公司章程》（以下简称《公司章程》）的有关规定，指派律师出席了公司于2025 年5月6日召开的2024年度股东大会（以下简称本次股东大会），并就本次股东大 会的相关事项出具本法律意见书。 1. 经公司 2023 年度股东大会审议通过的《公司章程》； 2. 公司 2025 年 4 月 9 日披露于巨潮资讯网（http://www.cninfo.com.cn，下 同）及深圳证券交易所网站（http://www.szse.cn/，下同）的《宁波戴维医疗器 械股份有限公司第五届董事会第十一次会议决议的公告》； 3. 公司 2025 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-028 宁波戴维医疗器械股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 （1）现场会议召开时间：2025 年 5 月 6 日（星期二）14:00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时 间为：2025年5月6日的交易时间，即9:15-9:25,9:30-11:30和13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年5月6日 9:15至15:00的任意时间。 2、现场会议召开地点：浙江省宁波市象山县石浦科技园区科苑路2号 公司会议室。 3、会议召开方式：本次股东大会采取现场投票与网络投票相结合的方 式召开。 4、会议召集人：公司董事会。 5、会议主持人：公司董事长陈再宏先生。 6、本次会议的召集、召开与表决程序符合有关法律、行政法 ...